OliX and Lilly Enter Global Licensing Agreement for MASH and …
2 days ago · OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016. ... 226950), a leading developer of …
Lilly inks AdvanCell, OliX deals to expand in radiopharma, MASH
2 days ago · Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on …
OliX
2 days ago · SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global …
Lilly and Olix Ink $630M Deal for Early-Stage MASH Candidate
1 day ago · OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly for the development and commercialization of OliX’s OLX75016, a Phase I candidate primarily …
Eli Lilly enters global license agreement with OliX for OLX75016
2 days ago · OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly . This collaboration focuses on the development and commercialization of OliX’s OLX75016, a …
Olix, Eli Lilly to develop liver disease drug under $630 million deal
2 days ago · Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly and Company to develop and commercialize treatments targeting cardiovascular and metabolic diseases. …
OliX strikes $630 million deal with Lilly for obesity and liver disease ...
2 days ago · OliX Pharmaceuticals, a Korean biotech company specializing in RNA interference (RNAi) therapies, has signed an exclusive global licensing deal with Eli Lilly worth up to $630 …
OliX and Lilly Enter Global Licensing Agreement for MASH and …
1 day ago · OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company …
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
1 day ago · Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its …
Olix, US Eli Lilly Sign MASH and Cardiovascular and Metabolic …
1 day ago · Olix (225950), a breakthrough drug development company based on RNA interference technology, announced today (7th) that it has signed a global licensing agreement …
- Some results have been removed
